Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Advances Pipeline With Yondelis, Carisbamate Filings

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Johnson & Johnson progressed its pipeline with the filing of two novel drugs late in 2008: trabectedin (marketed outside the U.S. as Yondelis) for the treatment of relapsed ovarian cancer, and carisbamate for the adjunctive treatment of partial onset seizures

You may also be interested in...



FDA To Centocor: Show Me The REMS

Ustekinumab “complete response” letter requests medication guide and communication plan, but not restricted distribution.

Paliperidone Palmitate Launch Unlikely Until 2010, J&J Says

New dosing option for the atypical antipsychotic will be included in the NDA resubmission.

J&J Cautious On Paliperidone Palmitate

Could management’s lack of enthusiasm for the schizophrenia drug foreshadow a delay at FDA?

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS004066

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel